Healthcare Industry News:   Hologic 

Devices Radiology Distribution

 News Release - May 15, 2007

Medipattern Continues to Expand Global Reseller Network

B-CAD(TM) will be available in Mexico and Korea

TORONTO, ONTARIO--(Healthcare Sales & Marketing Network)--May 15, 2007 -- Attention: Business/Financial Editors The Medipattern Corporation (CDNX:MKI.V ), an award-winning developer of computer-aided diagnosis (CAD) software, whose mission is to reduce the number of unnecessary biopsies performed to diagnose cancer, is pleased to announce the signing of distribution agreements with Electronica y Medicina, S.A. (EYMSA), headquartered in Mexico; D.F., Mexico; and Dong Jin Medical Co., Ltd., based in Seoul, Korea. These agreements are part of Medipattern's comprehensive strategy to establish a global distribution network for its products.

EYMSA was founded in 1979, and has four divisions and a staff of 170 employees. In Mexico, breast cancer incidence has been rising over the past decade. According to the World Heath Organization's statistics, the breast cancer mortality rate in Mexico is 8.9 per 1000 women or 429,000 women this year.

"Recent studies have shown that women of Hispanic heritage have increased risk of breast cancer and are more resistant to the most frequently used treatments," said Cuauhtemoc Monroy Rivera, Sales Manager of EYMSA. "Mexico needs the capability of diagnosing breast cancer in younger women and ultrasound is the best technology for that purpose. But it is very susceptible to various interpretations and is not standardized. B-CAD brings standardization to interpreting the images and adds the expertise of CAD to help every radiologist in understanding the images presented during each exam."

Dong Jin Medical Co. Ltd. was founded in 1989, and has three divisions with a staff of 20 employees. Dong Jin also represents Hologic and Mavig as well as products developed locally for the Korean medical market.

"Breast ultrasound is widely used in Korea today," said J. W. Kim, Managing Director of Dong Jin Medical. "The methodology behind the BI-RADS® lexicon (the American College of Radiology's breast imaging template) brings diagnostic capability to breast ultrasound and B-CAD will help widespread adoption of the lexicon. B-CAD can be used to train practitioners in BI-RADS® and then streamline the process to make ultrasound easy to use and increase its effectiveness."

"B-CAD is proving itself as an effective tool to standardize interpreting and reporting breast ultrasound cases. We are pleased to have such reputable companies to represent our product in their respective territories. They all have a history of exceptional performance and a dedication to ultrasound and women's imaging," said Jeff Collins, CEO of The Medipattern Corporation.

Upcoming Events:

Medipattern is participating in the following events:

- Breast Imaging Symposium, May 25 to 28 Puerto Rico.

- Breast Imaging Conference, September 10-13, San Diego, CA.

- Chicago International Breast Imaging Symposium October 3 to 7, 2007, Chicago, IL.

- RSNA, November 25 to 29, 2007, Chicago, IL.

About The Medipattern Corporation

Medipattern develops computer-aided diagnosis (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD(TM) for breast ultrasound and B-CAD MRI(TM). Both have received awards for innovation in the industry. The B-CAD products, part of the Company's CADENZA platform, use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. Medipattern's mission is to design software products that reduce the number of unnecessary biopsies performed in the detection of cancer. Please visit the company's website at:

B-CAD(TM) and B-CAD MRI(TM) are trademarks of The Medipattern Corporation.

Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Source: Medipattern

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.